Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Bela M. Medvedeva"'
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 96-100 (2021)
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibi
Externí odkaz:
https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7
Autor:
Dzhamal T Abdurakhmanov, Valerii V Breder, Larisa V Bolotina, Vladislav Iu Kosyrev, Bela M Medvedeva, Vladislav V Petkau
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 10-16 (2019)
Hepatocellular carcinoma (HCC) is the most common liver malignancy and ranks sixth for cancer prevalence and fourth place among the causes of cancer mortality. Despite the improvement of diagnostic techniques, the diagnosis of HCC is still determined
Externí odkaz:
https://doaj.org/article/3fc20795226245f58d9ce6be742c2245
Publikováno v:
Современная онкология, Vol 22, Iss 4, Pp 96-100 (2021)
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibi
Autor:
Valerii V. Breder, Larisa Bolotina, Bela M. Medvedeva, D.T. Abdurakhmanov, Vladislav V Petkau, Vladislav Iu Kosyrev
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 10-16 (2019)
Hepatocellular carcinoma (HCC) is the most common liver malignancy and ranks sixth for cancer prevalence and fourth place among the causes of cancer mortality. Despite the improvement of diagnostic techniques, the diagnosis of HCC is still determined